, Volume 57, Issue 1, pp 83–87

Haloperidol and lithium blocking of the mood response to intravenous methylphenidate

  • David Wald
  • Richard P. Ebstein
  • Robert H. Belmaker


Ten euthymic manic-depressive patients with therapeutic plasma lithium levels were each given two i.v. infusions of 30 mg of methylphenidate. The infusions were separated by at least 3 days. Before one infusion each patient was given 5 mg of haloperidol i.v. and before the other infusion each was given an identical volume of saline. A psychiatric observer was blind to the nature of the pretreatment and the order of pretreatment was randomized. Saline pretreated patients showed marked activation and euphoriant responses despite therapeutic lithium levels. Haloperidol pretreatment reduced this response in three patients and eliminated the euphoriant and activating response in the remaining seven patients. These results agree with the existence of a dopaminergic step in the induction of methylphenidate-induced activation and euphoria.

Key words

Methylphenidate Haloperidol Lithium Euphoria Manic-depressive Dopamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andén, N.-E., Butcher, S. G., Corrodi, H., Fuxe, K., Ungerstedt, U.: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur. J. Pharmacol. 11, 303–314 (1970)Google Scholar
  2. Angrist, B. M., Sathanathan, G., Wilk, S., Gershon, S.: Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11, 13–23 (1974)Google Scholar
  3. Belmaker, R. H., Ebstein, R. P., Schoenfeld, H., Rimon, R.: The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans. Psychopharmacology 49, 215–217 (1976)Google Scholar
  4. Belmaker, R. H., Wald, D.: Haloperidol in normals. Br. J. Psychiatry 131, 222 (1977)Google Scholar
  5. Davies, C., Sanger, D. L., Steinberg, H., Tomkiewicz, M., U'Prichard, D. C.: Lithium and α-methyl-p-tyrosine prevent “manic” activity in rodents. Psychopharmacologia (Berl.) 36, 263–274 (1974)Google Scholar
  6. Dunner, D. L., Fieve, R. R.: Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiatry 30, 229–233 (1974)Google Scholar
  7. Furukawa, T., Ushizima, I., Ono, N.: Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine. Psychopharmacologia (Berl.) 42, 243–248 (1975)Google Scholar
  8. Gerner, R. H., Post, R. M., Bunney, W. E., Jr.: A dopaminergic mechanism in mania. Am. J. Psychiatry 133, 1177–1180 (1976)Google Scholar
  9. Jasinski, D. R., Nutt, J. G., Haertzen, C. A., Griffith, J. D.: Lithium: effects on subjective functioning and morphine-induced euphoria. Science 195, 582–584 (1977)Google Scholar
  10. Jonsson, L. E., Anggard, E., Gunne, L. M.: Blockade of intravenous amphetamine euphoria in man. Clin. Pharmacol. Ther. 12, 889–896 (1971)Google Scholar
  11. Kadouch, R., Belmaker, R. H., Ebstein, R. P., Perez, L.: The mood response and plasma cyclic AMP response to intravenous methylphenidate. Neuropsychobiology 3, 250–255 (1977)Google Scholar
  12. Martin, W. R., Sloan, J. W., Sapira, J. D., Jasinski, D. R.: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245–258 (1971)Google Scholar
  13. Oppenheim, G., Ebstein, R. P., Belmaker, R. H.: The effect of lithium on physostigmine-induced behavioral syndrome and plasma cyclic GMP. J. Psychiatr. Res. (in press, 1978)Google Scholar
  14. Peet, M.: Lithium in the acute treatment of mania. In: Lithium research and therapy, F. N. Johnson, ed. pp. 25–41. London: Academic Press 1975Google Scholar
  15. Pijnenburg, A. J. J., Honig, W. M. M., Rossum, J. M. van: Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia (Berl.) 41, 87–95 (1975)Google Scholar
  16. Post, R. M.: Cocaine psychoses: a continuum model. Am. J. Psychiatry 132, 225–231 (1975)Google Scholar
  17. Prien, R. F.: The clinical effectiveness of lithium: comparisons with other drugs. In: Lithium research and therapy, F. N. Johnson, ed., pp. 99–113. London: Academic Press 1975Google Scholar
  18. Scheel-Kruger, J.: Some aspects of the mechanism of action of various stimulant amphetamine analogues. Psychiatr. Neurol. Neurochir. (Amst.) 75, 179–192 (1972)Google Scholar
  19. Schildkraut, J. J.: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry. 122, 509–522 (1965)Google Scholar
  20. Shaw, D. M.: Lithium and amine metabolism. In: Lithium research and therapy, F. N. Johnson, ed., pp. 411–423. London: Academic Press 1975Google Scholar
  21. Shopsin, B., Gershon, S., Thompson, H., Collins, P.: Psychoactive drugs in mania. Arch. Gen. Psychiatry 32, 34–42 (1975)Google Scholar
  22. Snyder, S. H., Banerjee, S. P., Yamamura, H. I., Greenberg, D.: Drugs, neurotransmitters and schizophrenia. Science 184, 1243–1253 (1974)Google Scholar
  23. Tecce, J. J., Cole, J. O.: Amphetamine effects in man: paradoxal drowsiness and lowered electrical brain activity (CNV). Science 185, 451–453 (1974)Google Scholar
  24. Thornsburg, J. E., Moore, K. E.: The relative importance of dopaminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. Neuropharmacology 12, 853–866 (1973)Google Scholar
  25. Van Kammen, D. P., Murphy, D. L.: Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia (Berl.) 44, 215–224 (1975)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • David Wald
    • 1
  • Richard P. Ebstein
    • 1
  • Robert H. Belmaker
    • 1
  1. 1.Jerusalem Mental Health Center-Ezrat NashimJerusalemIsrael

Personalised recommendations